ZYME
$24.04
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
Recent News
Zymeworks Leans On Zanidatamab Results To Build Royalty Focused Model
Zymeworks (NasdaqGS:ZYME) reported positive Phase 3 results for partnered HER2 antibody zanidatamab. The company indicated it is working toward a potential U.S. approval and launch in the second half of 2026. Zymeworks entered a $250 million non recourse royalty backed note financing agreement with Royalty Pharma. The company is shifting to a hybrid business model focused on partnerships and a diversified royalty portfolio. Zymeworks also filed a shelf registration to keep options open for...
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience
Despite a net loss, Zymeworks Inc (ZYME) showcases strong revenue growth, strategic financing, and promising pipeline advancements.
Zymeworks Q4 Earnings Call Highlights
Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatamab, outline a new royalty-backed financing with Royalty Pharma, and provide 2025 financial results and pipeline updates across multiple e
Zymeworks Inc. Q4 2025 Earnings Call Summary
Moby summary of Zymeworks Inc.'s Q4 2025 earnings call
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -58.64% and -88.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?